Home > Cardiology > ESC 2020 > COVID and Cardiovascular Disease > COVID-19 treatments and the importance of randomised trials

COVID-19 treatments and the importance of randomised trials

Presented By
Prof. Martin Landray, University of Oxford, UK
Conference
ESC 2020
Trial
RECOVERY
Currently, just two COVID-19 treatments have shown benefit in randomised trials: remdesivir and dexamethasone. No benefit was found for hydroxychloroquine, lopinavir-ritonavir, and tocilizumab. Prof. Martin Landray (University of Oxford, United Kingdom) gave an overview of randomised trials of COVID-19 treatments with a focus on hospitalised patients [1]. For most people, an infection with SARS-CoV-2 is self-limiting, but for hospitalised patients, mortality is high (10-20%) and for ventilated patients even higher (40-50%). The pathophysiology of COVID-19 is characterised by 2 components: a viral response in the first week to 10 days, and an increasing inflammatory response, where the immune system is initially combating the virus but can also drive lung damage and need for ventilation. Current treatment falls into 3 categories: repurposed anti-virals, immunomodulatory drugs, and some drugs targeted specifically at SARS-CoV-2. In addition, there are...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on